CRIXIVAN®
(INDINAVIR SULFATE)
CAPSULES

DESCRIPTION

CRIXIVAN® (indinavir sulfate) is an inhibitor of the human immunodeficiency virus (HIV) protease. CRIXIVAN Capsules are formulated as a sulfate salt and are available for oral administration in strengths of 100, 200, 333, and 400 mg of indinavir (corresponding to 125, 250, 416.3, and 500 mg indinavir sulfate, respectively). Each capsule also contains the inactive ingredients anhydrous lactose and magnesium stearate. The capsule shell has the following inactive ingredients and dyes: gelatin, titanium dioxide, silicon dioxide and sodium lauryl sulfate.

The chemical name for indinavir sulfate is \[1(1S,2R,5(S))-2,3,5-trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-[2-[[1,1-dimethylethyl]amino]carbonyl]-4-(3-pyridinylmethyl)-1-piperazinyl]-2-(phenylmethyl)-D-erythro-pentonamide sulfate (1:1) salt. Indinavir sulfate has the following structural formula:

\[
\text{Indinavir sulfate is a white to off-white, hygroscopic, crystalline powder with the molecular formula } C_{36}H_{47}N_5O_4 \cdot H_2SO_4 \text{ and a molecular weight of 711.88. It is very soluble in water and in methanol.}
\]

MICROBIOLOGY

Mechanism of Action: HIV-1 protease is an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Indinavir binds to the protease active site and inhibits the activity of the enzyme. This inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature non-infectious viral particles.

Antiretroviral Activity In Vitro: The in vitro activity of indinavir was assessed in cell lines of lymphoblastic and monocytic origin and in peripheral blood lymphocytes. HIV-1 variants used to infect the different cell types include laboratory-adapted variants, primary clinical isolates and clinical isolates resistant to nucleoside analogue and nonnucleoside inhibitors of the HIV-1 reverse transcriptase. The IC95 (95% inhibitory concentration) of indinavir in these test systems was in the range of 25 to 100 nM. In drug combination studies with the nucleoside analogues zidovudine and didanosine, indinavir showed synergistic activity in cell culture. The relationship between in vitro susceptibility of HIV-1 to indinavir and inhibition of HIV-1 replication in humans has not been established.

Drug Resistance: Isolates of HIV-1 with reduced susceptibility to the drug have been recovered from some patients treated with indinavir. Viral resistance was correlated with the accumulation of
mutations that resulted in the expression of amino acid substitutions in the viral protease. Eleven amino acid residue positions, (L10I/V/R, K20I/M/R, L24I, M46L/I, I54A/V, L63P, I64V, A71T/V, V82A/F/T, I84V, and L90M), at which substitutions are associated with resistance, have been identified. Resistance was mediated by the co-expression of multiple and variable substitutions at these positions. No single substitution was either necessary or sufficient for measurable resistance (≥4-fold increase in IC₅₀). In general, higher levels of resistance were associated with the co-expression of greater numbers of substitutions, although their individual effects varied and were not additive. At least 3 amino acid substitutions must be present for phenotypic resistance to indinavir to reach measurable levels. In addition, mutations in the p7/p1 and p1/p6 gag cleavage sites were observed in some indinavir resistant HIV-1 isolates.

In vitro phenotypic susceptibilities to indinavir were determined for 38 viral isolates from 13 patients who experienced virologic rebounds during indinavir monotherapy. Pre-treatment isolates from five patients exhibited indinavir IC₅₀ values of 50-100 nM. At or following viral RNA rebound (after 12-76 weeks of therapy), IC₅₀ values ranged from 25 to >3000 nM, and the viruses carried 2 to 10 mutations in the protease gene relative to baseline.

Cross-Resistance to Other Antiviral Agents: Varying degrees of HIV-1 cross-resistance have been observed between indinavir and other HIV-1 protease inhibitors. In studies with ritonavir, saquinavir, and amprenavir, the extent and spectrum of cross-resistance varied with the specific mutational patterns observed. In general, the degree of cross-resistance increased with the accumulation of resistance-associated amino acid substitutions. Within a panel of 29 viral isolates from indinavir-treated patients that exhibited measurable (≥4-fold) phenotypic resistance to indinavir, all were resistant to ritonavir. Of the indinavir resistant HIV-1 isolates, 63% showed resistance to saquinavir and 81% to amprenavir.

**CLINICAL PHARMACOLOGY**

**Pharmacokinetics**

**Absorption:** Indinavir was rapidly absorbed in the fasted state with a time to peak plasma concentration (T_max) of 0.8 ± 0.3 hours (mean ± S.D.) (n=11). A greater than dose-proportional increase in indinavir plasma concentrations was observed over the 200-1000 mg dose range. At a dosing regimen of 800 mg every 8 hours, steady-state area under the plasma concentration time curve (AUC) was 30,691 ± 11,407 nM•hour (n=16), peak plasma concentration (C_max) was 12,617 ± 4037 nM (n=16), and plasma concentration eight hours post dose (trough) was 251 ± 178 nM (n=16).

**Effect of Food on Oral Absorption:** Administration of indinavir with a meal high in calories, fat, and protein (784 kcal, 48.6 g fat, 31.3 g protein) resulted in a 77% ± 8% reduction in AUC and an 84% ± 7% reduction in C_max (n=10). Administration with lighter meals (e.g., a meal of dry toast with jelly, apple juice, and coffee with skim milk and sugar or a meal of corn flakes, skim milk and sugar) resulted in little or no change in AUC, C_max or trough concentration.

**Distribution:** Indinavir was approximately 60% bound to human plasma proteins over a concentration range of 81 nM to 16,300 nM.

**Metabolism:** Following a 400-mg dose of ¹⁴C-indinavir, 83 ± 1% (n=4) and 19 ± 3% (n=6) of the total radioactivity was recovered in feces and urine, respectively; radioactivity due to parent drug in feces and urine was 19.1% and 9.4%, respectively. Seven metabolites have been identified, one glucuronide conjugate and six oxidative metabolites. In vitro studies indicate that cytochrome P-450 3A4 (CYP3A4) is the major enzyme responsible for formation of the oxidative metabolites.

**Elimination:** Less than 20% of indinavir is excreted unchanged in the urine. Mean urinary excretion of unchanged drug was 10.4 ± 4.9% (n=10) and 12.0 ± 4.9% (n=10) following a single 700-mg and 1000-mg dose, respectively. Indinavir was rapidly eliminated with a half-life of 1.8 ± 0.4 hours (n=10). Significant accumulation was not observed after multiple dosing at 800 mg every 8 hours.

**Special Populations**

**Hepatic Insufficiency:** Patients with mild to moderate hepatic insufficiency and clinical evidence of cirrhosis had evidence of decreased metabolism of indinavir resulting in approximately 60% higher mean AUC following a single 400-mg dose (n=12). The half-life of indinavir increased to
2.8 ± 0.5 hours. Indinavir pharmacokinetics have not been studied in patients with severe hepatic insufficiency (see DOSAGE AND ADMINISTRATION, Hepatic Insufficiency).

Renal Insufficiency: The pharmacokinetics of indinavir have not been studied in patients with renal insufficiency.

Gender: The effect of gender on the pharmacokinetics of indinavir was evaluated in 10 HIV seropositive women who received CRIXIVAN 800 mg every 8 hours with zidovudine 200 mg every 8 hours and lamivudine 150 mg twice a day for one week. Indinavir pharmacokinetic parameters in these women were compared to those in HIV seropositive men (pooled historical control data). Differences in indinavir exposure, peak concentrations, and trough concentrations between males and females are shown in Table 1 below:

<table>
<thead>
<tr>
<th>PK Parameter</th>
<th>% change in PK parameter for females relative to males</th>
<th>90% Confidence Interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>AUC$_{0-8h}$ (nM•hr)</td>
<td>↓13%</td>
<td>(↓32%, ↑12%)</td>
</tr>
<tr>
<td>C$_{max}$ (nM)</td>
<td>↓13%</td>
<td>(↓32%, ↑10%)</td>
</tr>
<tr>
<td>C$_{8h}$ (nM)</td>
<td>↓22%</td>
<td>(↓47%, ↑15%)</td>
</tr>
</tbody>
</table>

↓Indicates a decrease in the PK parameter; ↑indicates an increase in the PK parameter.

The clinical significance of these gender differences in the pharmacokinetics of indinavir is not known.

Race: Pharmacokinetics of indinavir appear to be comparable in Caucasians and Blacks based on pharmacokinetic studies including 42 Caucasians (26 HIV-positive) and 16 Blacks (4 HIV-positive).

Pediatric: The optimal dosing regimen for use of indinavir in pediatric patients has not been established. In HIV-infected pediatric patients (age 4-15 years), a dosage regimen of indinavir capsules, 500 mg/m$^2$ every 8 hours, produced AUC$_{0-8h}$ of 38,742 ± 24,098 nM•hour (n=34), C$_{max}$ of 17,181 ± 9809 nM (n=34), and trough concentrations of 134 ± 91 nM (n=28). The pharmacokinetic profiles of indinavir in pediatric patients were not comparable to profiles previously observed in HIV-infected adults receiving the recommended dose of 800 mg every 8 hours. The AUC and C$_{max}$ values were slightly higher and the trough concentrations were considerably lower in pediatric patients. Approximately 50% of the pediatric patients had trough values below 100 nM; whereas, approximately 10% of adult patients had trough levels below 100 nM. The relationship between specific trough values and inhibition of HIV replication has not been established.

Drug Interactions (also see PRECAUTIONS, Drug Interactions)

Specific drug interaction studies were performed with indinavir and a number of drugs.

Drugs That Should Not Be Coadministered With CRIXIVAN

Administration of indinavir (800 mg every 8 hours) with rifampin (600 mg once daily) for one week resulted in an 89% ± 9% decrease in indinavir AUC.

In a published study, eight HIV-negative volunteers received indinavir 800 mg every eight hours for four doses prior to and at the end of a 14-day course of St. John’s wort (Hypericum perforatum, standardized to 0.3% hypericin) 300 mg three times daily. Indinavir plasma pharmacokinetics were determined following the fourth dose of indinavir prior to and following St. John’s wort. Following the course of St. John’s wort, the AUC$_{0-8h}$ of indinavir was decreased 57% ± 19% and the C$_{8h}$ of indinavir was decreased 81% ± 16% compared to when indinavir was taken alone. All subjects demonstrated a decrease in AUC$_{0-8h}$ (range 36 to 79%) and a decrease in C$_{8h}$ (range 49 to 99%). (See WARNINGS.)

Drugs Requiring Dose Modification

Delavirdine: Preliminary data (n=14) indicate that delavirdine inhibits the metabolism of indinavir such that coadministration of a 400-mg single dose of indinavir with delavirdine (400 mg three times a day) resulted in indinavir AUC values slightly less than those observed following administration of an 800-mg dose of indinavir alone. Also, coadministration of a 600-mg dose of indinavir with delavirdine (400 mg three times a day) resulted in indinavir AUC values approximately 40% greater than those observed following administration of an 800-mg dose of
indinavir alone. Indinavir had no effect on delavirdine pharmacokinetics (see DOSAGE AND ADMINISTRATION, Concomitant Therapy, Delavirdine).

Efavirenz: When indinavir (800 mg every 8 hours) was given with efavirenz (200 mg once daily) for two weeks, the indinavir AUC and C_max were decreased by approximately 31% and 16%, respectively, as a result of enzyme induction. (See DOSAGE AND ADMINISTRATION, Concomitant Therapy, Efavirenz.)

Sildenafil: The results of one published study in HIV-infected men (n=6) indicated that coadministration of indinavir (800 mg every 8 hours chronically) with a single 25-mg dose of sildenafil resulted in an 11% increase in average AUC_0-8hr of indinavir and a 48% increase in average indinavir peak concentration (C_max) compared to 800 mg every 8 hours alone. Average sildenafil AUC was increased by 340% following coadministration of sildenafil and indinavir compared to historical data following administration of sildenafil alone (see PRECAUTIONS, Drug Interactions).

Itraconazole: In a multiple-dose study, administration in the fasted state of itraconazole capsules 200 mg twice daily with indinavir 600 mg every 8 hours resulted in an indinavir AUC similar to that observed during administration of indinavir 800 mg every 8 hours alone for one week (see DOSAGE AND ADMINISTRATION, Concomitant Therapy, Itraconazole).

Ketoconazole: In a single-dose study, administration of a 400-mg dose of ketoconazole with a 400-mg dose of indinavir resulted in a 68% ± 48% increase in indinavir AUC compared to a 400-mg dose of indinavir alone. In a multiple-dose study, administration of ketoconazole 400 mg once daily with indinavir 600 mg every 8 hours resulted in an 18% ± 17% decrease in indinavir AUC compared to an 800-mg dose of indinavir alone every 8 hours (see DOSAGE AND ADMINISTRATION, Concomitant Therapy, Ketoconazole).

Rifabutin: The coadministration of indinavir 800 mg every 8 hours with rifabutin either 300 mg once daily or 150 mg once daily was evaluated in two separate clinical studies. The results of these studies showed a decrease in indinavir AUC (32% ± 19% and 31% ± 15%, respectively) vs. indinavir 800 mg every 8 hours alone and an increase in rifabutin AUC (204% ± 142% and 60% ± 47%, respectively) vs. rifabutin 300 mg once daily alone. (See DOSAGE AND ADMINISTRATION, Concomitant Therapy, Rifabutin.)

Drugs Not Requiring Dose Modification

Cimetidine, Quinidine, Grapefruit Juice: Administration of a single 400-mg dose of indinavir following six days of cimetidine (600 mg every 12 hours) did not affect indinavir AUC. Administration of a single 400-mg dose of indinavir with 8 oz. of grapefruit juice resulted in a decrease in indinavir AUC (26% ± 18%). Administration of a single 400-mg dose of indinavir with 200 mg of quinidine sulfate resulted in a 10% ± 26% increase in indinavir AUC.

Methadone: Administration of indinavir (800 mg every 8 hours) with methadone (20 mg to 60 mg daily) for one week resulted in no change in methadone AUC and little or no change in indinavir AUC.

Nucleoside analogue antiretroviral agents: Administration of indinavir (1000 mg every 8 hours) with zidovudine (200 mg every 8 hours) for one week resulted in a 13% ± 48% increase in indinavir AUC and a 17% ± 23% increase in zidovudine AUC. In another study, administration of indinavir (800 mg every 8 hours) with zidovudine (200 mg every 8 hours) in combination with lamivudine (150 mg twice daily) for one week resulted in no change in indinavir AUC, a 36% increase in zidovudine AUC, and a 6% decrease in lamivudine AUC. Administration of indinavir (800 mg every 8 hours) in combination with stavudine (40 mg every 12 hours) for one week resulted in no change in stavudine AUC and a 25% ± 26% increase in stavudine AUC.

ORTHO-NOVUM 1/35: Administration of indinavir (800 mg every 8 hours) with ORTHO-NOVUM 1/35 for one week resulted in a 24% ± 17% increase in ethinyl estradiol AUC and a 26% ± 14% increase in norethindrone AUC.

Trimethoprim/Sulfamethoxazole, Fluconazole, Isoniazid, Clarithromycin: Administration of indinavir (400 mg every 6 hours) with trimethoprim/sulfamethoxazole (one double strength tablet every 12 hours) for one week resulted in no change in indinavir AUC, a 19% ± 31% increase in trimethoprim AUC, and no change in sulfamethoxazole AUC. Administration of indinavir (1000 mg
every 8 hours) with fluconazole (400 mg once daily) for one week resulted in a 19% ± 33% decrease in indinavir AUC and no change in fluconazole AUC. Administration of indinavir (800 mg every 8 hours) with isoniazid (300 mg once daily) for one week resulted in no change in indinavir AUC and a 13% ± 15% increase in isoniazid AUC. Administration of indinavir (800 mg every 8 hours) with clarithromycin (500 mg every 12 hours) for one week resulted in a 29% ± 42% increase in indinavir AUC and a 53% ± 36% increase in clarithromycin AUC.

INDICATIONS AND USAGE

CRIXIVAN in combination with antiretroviral agents is indicated for the treatment of HIV infection.

This indication is based on two clinical trials of approximately 1 year duration that demonstrated: 1) a reduction in the risk of AIDS-defining illnesses or death; 2) a prolonged suppression of HIV RNA.

Description of Studies

In all clinical studies, with the exception of ACTG 320, the AMPLICOR HIV MONITOR assay was used to determine the level of circulating HIV RNA in serum. This is an experimental use of the assay. HIV RNA results should not be directly compared to results from other trials using different HIV RNA assays or using other sample sources.

Study ACTG 320 was a multicenter, randomized, double-blind clinical endpoint trial to compare the effect of CRIXIVAN in combination with zidovudine and lamivudine with that of zidovudine plus lamivudine on the progression to an AIDS-defining illness (ADI) or death. Patients were protease inhibitor and lamivudine naive and zidovudine experienced, with CD4 cell counts of ≤200 cells/mm³. The study enrolled 1156 HIV-infected patients (17% female, 28% Black, 18% Hispanic, mean age 39 years). The mean baseline CD4 cell count was 87 cells/mm³. The mean baseline HIV RNA was 4.95 log₁₀ copies/mL (89,035 copies/mL). The study was terminated after a planned interim analysis, resulting in a median follow-up of 38 weeks and a maximum follow-up of 52 weeks. Results are shown in Table 2 and Figures 1 & 2.

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>ACTG 320</th>
</tr>
</thead>
<tbody>
<tr>
<td>IDV+ZDV+L (n=577)</td>
<td>ZDV+L (n=579)</td>
</tr>
<tr>
<td>HIV Progression or Death</td>
<td>35 (6.1)</td>
</tr>
<tr>
<td>Death*</td>
<td>10 (1.7)</td>
</tr>
</tbody>
</table>

* The number of deaths is inadequate to assess the impact of Indinavir on survival.

IDV = Indinavir, ZDV = Zidovudine, L = Lamivudine
Study 028, a double-blind, multicenter, randomized, clinical endpoint trial conducted in Brazil, compared the effects of CRIXIVAN plus zidovudine with those of CRIXIVAN alone or zidovudine alone on the progression to an ADI or death, and on surrogate marker responses. All patients were antiretroviral naive with CD4 cell counts of 50 to 250 cells/mm$^3$. The study enrolled 996 HIV-1 seropositive patients [28% female, 11% Black, 1% Asian/Other, median age 33 years, mean baseline CD4 cell count of 152 cells/mm$^3$, mean serum viral RNA of 4.44 log$_{10}$ copies/mL (27,824 copies/mL)]. Treatment regimens containing zidovudine were modified in a blinded manner with the optional addition of lamivudine (median time: week 40). The median length of follow-up was 56 weeks with a maximum of 97 weeks. The study was terminated after a planned interim analysis, resulting in a median follow-up of 56 weeks and a maximum follow-up of 97 weeks. Results are shown in Table 3 and Figures 3 and 4.
Table 3
Protocol 028

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>IDV+ZDV (n=332)</th>
<th>IDV (n=332)</th>
<th>ZDV (n=332)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV Progression or Death</td>
<td>21 (6.3)</td>
<td>27 (8.1)</td>
<td>62 (18.7)</td>
</tr>
<tr>
<td>Death*</td>
<td>8 (2.4)</td>
<td>5 (1.5)</td>
<td>11 (3.3)</td>
</tr>
</tbody>
</table>

* The number of deaths is inadequate to assess the impact of Indinavir on survival.

Study 028: Figure 3

Indinavir Protocol 028 Zidovudine Naive
Viral RNA - Proportions Below 500 Copies/mL in Serum

![Graph showing viral RNA levels](image)

Study 028: Figure 4

Indinavir Protocol 028 Zidovudine Naive
CD4 Cell Counts - Mean Change from Baseline

![Graph showing CD4 cell counts](image)

Study 035 was a multicenter randomized trial in 97 HIV-1 seropositive patients who were zidovudine-experienced (median exposure 30 months), protease-inhibitor- and lamivudine-naive, with mean baseline CD4 count 175 cells/mm$^3$ and mean baseline serum viral RNA 4.62 log$_{10}$.
Comparisons included CRIXIVAN plus zidovudine plus lamivudine vs. CRIXIVAN alone vs. zidovudine plus lamivudine. After at least 24 weeks of randomized, double-blind therapy, patients were switched to open-label CRIXIVAN plus lamivudine plus zidovudine. Mean changes in $\log_{10}$ viral RNA in serum, the proportions of patients with viral RNA below 500 copies/mL in serum, and mean changes in CD4 cell counts, during 24 weeks of randomized, double-blind therapy are summarized in Figures 5, 6, and 7, respectively. A limited number of patients remained on randomized, double-blind treatment for longer periods; based on this extended treatment experience, it appears that a greater number of subjects randomized to CRIXIVAN plus zidovudine plus lamivudine demonstrated HIV RNA levels below 500 copies/mL during one year of therapy as compared to those in other treatment groups.

**Study 035: Figure 5**

*Indinavir Protocol 035 Zidovudine Experienced*

**Viral RNA - Mean Log10 Change from Baseline in Serum**

<table>
<thead>
<tr>
<th>Treatment</th>
<th>N</th>
<th>N</th>
<th>N</th>
</tr>
</thead>
<tbody>
<tr>
<td>IDV + ZDV + L</td>
<td>32</td>
<td>30</td>
<td>30</td>
</tr>
<tr>
<td>IDV</td>
<td>31</td>
<td>31</td>
<td>28</td>
</tr>
<tr>
<td>ZDV + L</td>
<td>33</td>
<td>33</td>
<td>30</td>
</tr>
</tbody>
</table>

**Study 035: Figure 6**

*Indinavir Protocol 035 Zidovudine Experienced*

**Viral RNA - Proportions Below 500 Copies/mL in Serum**
Genotypic Resistance in Clinical Studies

Study 006 (10/15/93-10/12/94) was a dose-ranging study in which patients were initially treated with CRIXIVAN at a dose of <2.4 g/day followed by 2.4 g/day. Study 019 (6/23/94-4/10/95) was a randomized comparison of CRIXIVAN 600 mg every 6 hours, CRIXIVAN plus zidovudine, and zidovudine alone. Table 4 shows the incidence of genotypic resistance at 24 weeks in these studies.

Table 4
Genotypic Resistance at 24 Weeks

<table>
<thead>
<tr>
<th>Treatment Group</th>
<th>Resistance to IDV n/N</th>
<th>Resistance to ZDV n/N</th>
</tr>
</thead>
<tbody>
<tr>
<td>IDV</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>&lt;2.4 g/day</td>
<td>31/37 (84%)</td>
<td>—</td>
</tr>
<tr>
<td>2.4 g/day</td>
<td>9/21 (43%)</td>
<td>1/17 (6%)</td>
</tr>
<tr>
<td>IDV/ZDV</td>
<td>4/22 (18%)</td>
<td>1/22 (5%)</td>
</tr>
<tr>
<td>ZDV</td>
<td>1/18 (6%)</td>
<td>11/17 (65%)</td>
</tr>
</tbody>
</table>

* N - includes patients with non-amplifiable virus at 24 weeks who had amplifiable virus at week 0.

CONTRAINDICATIONS

CRIXIVAN is contraindicated in patients with clinically significant hypersensitivity to any of its components.

CRIXIVAN should not be administered concurrently with terfenadine, cisapride, astemizole, triazolam, midazolam, pimozone, or ergot derivatives. Inhibition of CYP3A4 by CRIXIVAN could result in elevated plasma concentrations of these drugs, potentially causing serious or life-threatening reactions.

WARNINGS

 ALERT: Find out about medicines that should not be taken with CRIXIVAN. This statement is included on the product's bottle label.
Nephrolithiasis/Urolithiasis

Nephrolithiasis/urolithiasis has occurred with CRIXIVAN therapy. The cumulative frequency of nephrolithiasis is substantially higher in pediatric patients (29%) than in adult patients (12.4%; range across individual trials: 4.7% to 34.4%). The cumulative frequency of nephrolithiasis events increases with increasing exposure to CRIXIVAN; however, the risk over time remains relatively constant. In some cases, nephrolithiasis/urolithiasis has been associated with renal insufficiency or acute renal failure, pyelonephritis with or without bacteremia. If signs or symptoms of nephrolithiasis/urolithiasis occur, (including flank pain, with or without hematuria or microscopic hematuria), temporary interruption (e.g., 1-3 days) or discontinuation of therapy may be considered. Adequate hydration is recommended in all patients treated with CRIXIVAN. (See ADVERSE REACTIONS and DOSAGE AND ADMINISTRATION, Nephrolithiasis/Urolithiasis.)

Hemolytic Anemia

Acute hemolytic anemia, including cases resulting in death, has been reported in patients treated with CRIXIVAN. Once a diagnosis is apparent, appropriate measures for the treatment of hemolytic anemia should be instituted, including discontinuation of CRIXIVAN.

Hepatitis

Hepatitis including cases resulting in hepatic failure and death has been reported in patients treated with CRIXIVAN. Because the majority of these patients had confounding medical conditions and/or were receiving concomitant therapy(ies), a causal relationship between CRIXIVAN and these events has not been established.

Hyperglycemia

New onset diabetes mellitus, exacerbation of pre-existing diabetes mellitus and hyperglycemia have been reported during post-marketing surveillance in HIV-infected patients receiving protease inhibitor therapy. Some patients required either initiation or dose adjustments of insulin or oral hypoglycemic agents for treatment of these events. In some cases, diabetic ketoacidosis has occurred. In those patients who discontinued protease inhibitor therapy, hyperglycemia persisted in some cases. Because these events have been reported voluntarily during clinical practice, estimates of frequency cannot be made and a causal relationship between protease inhibitor therapy and these events has not been established.

Drug Interactions

Concomitant use of CRIXIVAN with lovastatin or simvastatin is not recommended. Caution should be exercised if HIV protease inhibitors, including CRIXIVAN, are used concurrently with other HMG-CoA reductase inhibitors that are also metabolized by the CYP3A4 pathway (e.g., atorvastatin or cerivastatin). The risk of myopathy including rhabdomyolysis may be increased when HIV protease inhibitors, including CRIXIVAN, are used in combination with these drugs.

Particular caution should be used when prescribing sildenafil in patients receiving indinavir. Coadministration of CRIXIVAN with sildenafil is expected to substantially increase sildenafil plasma concentrations and may result in an increase in sildenafil-associated adverse events, including hypotension, visual changes, and priapism (see PRECAUTIONS, Drug Interactions and Information for Patients, and the manufacturer’s complete prescribing information for sildenafil).

Concomitant use of CRIXIVAN and St. John’s wort (Hypericum perforatum) or products containing St. John’s wort is not recommended. Coadministration of CRIXIVAN and St. John’s wort has been shown to substantially decrease indinavir concentrations (see CLINICAL PHARMACOLOGY, Pharmacokinetics, Drugs That Should Not Be Coadministered With CRIXIVAN) and may lead to loss of virologic response and possible resistance to CRIXIVAN or to the class of protease inhibitors.

PRECAUTIONS

General

Indirect hyperbilirubinemia has occurred frequently during treatment with CRIXIVAN and has infrequently been associated with increases in serum transaminases (see also ADVERSE REACTIONS, Clinical Trials and Post-Marketing Experience). It is not known whether CRIXIVAN will exacerbate the physiologic hyperbilirubinemia seen in neonates. (See Pregnancy.)

During post-marketing surveillance of patients treated with indinavir, rare reports of interstitial nephritis with medullary calcification and cortical atrophy have been observed in patients with
asymptomatic severe leukocyturia (>100 cells/ high power field). In patients with asymptomatic severe leukocyturia, further evaluation may be warranted.

Coexisting Conditions

Patients with hemophilia: There have been reports of spontaneous bleeding in patients with hemophilia A and B treated with protease inhibitors. In some patients, additional factor VIII was required. In many of the reported cases, treatment with protease inhibitors was continued or restarted. A causal relationship between protease inhibitor therapy and these episodes has not been established. (See ADVERSE REACTIONS, Post-Marketing Experience.)

Patients with hepatic insufficiency due to cirrhosis: In these patients, the dosage of CRIXIVAN should be lowered because of decreased metabolism of CRIXIVAN (see DOSAGE AND ADMINISTRATION).

Patients with renal insufficiency: Patients with renal insufficiency have not been studied.

Fat Redistribution

Redistribution/accumulation of body fat including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and “cushingoid appearance” have been observed in patients receiving antiretroviral therapy. The mechanism and long-term consequences of these events are currently unknown. A causal relationship has not been established.

Information for Patients

A statement to patients and health care providers is included on the product’s bottle label.

ALERT: Find out about medicines that should NOT be taken with CRIXIVAN. A Patient Package Insert (PPI) for CRIXIVAN is available for patient information.

CRIXIVAN is not a cure for HIV infection and patients may continue to develop opportunistic infections and other complications associated with HIV disease. The long-term effects of CRIXIVAN are unknown at this time. CRIXIVAN has not been shown to reduce the risk of transmission of HIV to others through sexual contact or blood contamination.

Patients should be advised to remain under the care of a physician when using CRIXIVAN and should not modify or discontinue treatment without first consulting the physician. Therefore, if a dose is missed, patients should take the next dose at the regularly scheduled time and should not double this dose. Therapy with CRIXIVAN should be initiated and maintained at the recommended dosage.

CRIXIVAN may interact with some drugs; therefore, patients should be advised to report to their doctor the use of any other prescription, non-prescription medication or herbal products, particularly St. John’s wort.

For optimal absorption, CRIXIVAN should be administered without food but with water 1 hour before or 2 hours after a meal. Alternatively, CRIXIVAN may be administered with other liquids such as skim milk, juice, coffee, or tea, or with a light meal, e.g., dry toast with jelly, juice, and coffee with skim milk and sugar; or corn flakes, skim milk and sugar (see CLINICAL PHARMACOLOGY, Effect of Food on Oral Absorption and DOSAGE AND ADMINISTRATION). Ingestion of CRIXIVAN with a meal high in calories, fat, and protein reduces the absorption of indinavir.

Patients receiving sildenafil should be advised that they may be at an increased risk of sildenafil-associated adverse events including hypotension, visual changes, and priapism, and should promptly report any symptoms to their doctors.

Patients should be informed that redistribution or accumulation of body fat may occur in patients receiving antiretroviral therapy and that the cause and long-term health effects of these conditions are not known at this time.

CRIXIVAN Capsules are sensitive to moisture. Patients should be informed that CRIXIVAN should be stored and used in the original container and the desiccant should remain in the bottle.

Drug Interactions

Delavirdine

Due to an increase in indinavir plasma concentrations (preliminary results), a dosage reduction of indinavir should be considered when CRIXIVAN and delavirdine are coadministered. (See DOSAGE AND ADMINISTRATION, Concomitant Therapy, Delavirdine; CLINICAL PHARMACOLOGY, Drug Interactions, Drugs Requiring Dose Modification, Delavirdine.)
Efavirenz

Due to a decrease in the plasma concentrations of indinavir, a dosage increase of indinavir is recommended when CRIXIVAN and efavirenz are coadministered. No adjustment of the dose of efavirenz is necessary when given with indinavir. (See DOSAGE AND ADMINISTRATION, Concomitant Therapy, Efavirenz; CLINICAL PHARMACOLOGY, Drug Interactions, Drugs Requiring Dose Modification, Efavirenz.)

Erectile Dysfunction Agents

Particular caution should be used when prescribing sildenafil for patients receiving indinavir. The results of one published study in six HIV-infected subjects indicated that coadministration of indinavir (800 mg every 8 hours chronically) and sildenafil (25 mg as a single dose) resulted in increased indinavir and sildenafil concentrations. In two of the six subjects, prolonged clinical effects of sildenafil were noted for 72 hours after a single dose of sildenafil in combination with indinavir. Based on the results of this study, the dose of sildenafil should not exceed 25 mg in a 48-hour period. Patients receiving sildenafil should be advised that they are at an increased risk of sildenafil-associated adverse events including hypotension, visual changes, and priapism, and should promptly report any symptoms to their health care providers (see CLINICAL PHARMACOLOGY, Drug Interactions and WARNINGS).

Itraconazole

Itraconazole is an inhibitor of P-450 3A4 that increases plasma concentrations of indinavir. Therefore, a dosage reduction of indinavir is recommended when CRIXIVAN and itraconazole are coadministered (see DOSAGE AND ADMINISTRATION, Concomitant Therapy, Itraconazole; CLINICAL PHARMACOLOGY, Drug Interactions, Drugs Requiring Dose Modification, Itraconazole).

Ketoconazole

Ketoconazole is an inhibitor of P-450 3A4 that increases plasma concentrations of indinavir. Therefore, a dosage reduction of indinavir is recommended when CRIXIVAN and ketoconazole are coadministered (see DOSAGE AND ADMINISTRATION, Concomitant Therapy, Ketoconazole; CLINICAL PHARMACOLOGY, Drug Interactions, Drugs Requiring Dose Modification, Ketoconazole).

Rifabutin

When rifabutin and CRIXIVAN are coadministered, there is an increase in the plasma concentrations of rifabutin and a decrease in the plasma concentrations of indinavir. A dosage reduction of rifabutin and a dosage increase of CRIXIVAN are necessary when rifabutin is coadministered with CRIXIVAN. The suggested dose adjustments are expected to result in rifabutin concentrations at least 50% higher than typically observed when rifabutin is administered alone at its usual dose (300 mg/day) and indinavir concentrations which may be slightly less than typically observed when indinavir is administered alone at its usual dose (800 mg every 8 hours). (See DOSAGE AND ADMINISTRATION, Concomitant Therapy, Rifabutin; CLINICAL PHARMACOLOGY, Drug Interactions, Drugs Requiring Dose Modification, Rifabutin.)

Rifampin

Rifampin is a potent inducer of P-450 3A4 that markedly diminishes plasma concentrations of indinavir. Therefore, CRIXIVAN and rifampin should not be coadministered (see CLINICAL PHARMACOLOGY, Drugs That Should Not Be Coadministered With CRIXIVAN).

Calcium Channel Blockers

Calcium channel blockers are metabolized by CYP3A4 which is inhibited by indinavir. Coadministration of CRIXIVAN with calcium channel blockers may result in increased plasma concentrations of the calcium channel blockers which could increase or prolong their therapeutic and adverse effects.

Other

If CRIXIVAN and didanosine are administered concomitantly, they should be administered at least one hour apart on an empty stomach; a normal (acidic) gastric pH may be necessary for optimum absorption of indinavir, whereas acid rapidly degrades didanosine which is formulated with buffering agents to increase pH (consult the manufacturer’s product circular for didanosine).

Interactions between indinavir and less potent CYP3A4 inducers than rifampin, such as phenobarbital, phenytoin, carbamazepine, and dexamethasone have not been studied. These
agents should be used with caution if administered concomitantly with indinavir because decreased indinavir plasma concentrations may result.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenicity studies were conducted in mice and rats. In mice, no increased incidence of any tumor type was observed. The highest dose tested in rats was 640 mg/kg/day; at this dose a statistically significant increased incidence of thyroid adenomas was seen only in male rats. At that dose, daily systemic exposure in rats was approximately 1.3 times higher than daily systemic exposure in humans. No evidence of mutagenicity or genotoxicity was observed in in vitro microbial mutagenesis (Ames) tests, in vitro alkaline elution assays for DNA breakage, in vitro and in vivo chromosomal aberration studies, and in vitro mammalian cell mutagenesis assays. No treatment-related effects on mating, fertility, or embryo survival were seen in female rats and no treatment-related effects on mating performance were seen in male rats at doses providing systemic exposure comparable to or slightly higher than that with the clinical dose. In addition, no treatment-related effects were observed in fecundity or fertility of untreated females mated to treated males.

Pregnancy

Pregnancy Category C: Developmental toxicity studies were performed in rabbits (at doses up to 240 mg/kg/day), dogs (at doses up to 80 mg/kg/day), and rats (at doses up to 640 mg/kg/day). The highest doses in these studies produced systemic exposures in these species comparable to or slightly greater than human exposure. No treatment-related external, visceral, or skeletal changes were observed in rabbits or dogs. No treatment-related external or visceral changes were observed in rats. Treatment-related increases over controls in the incidence of supernumerary ribs (at exposures at or below those in humans) and of cervical ribs (at exposures comparable to or slightly greater than those in humans) were seen in rats. In all three species, no treatment-related effects on embryonic/fetal survival or fetal weights were observed.

In rabbits, at a maternal dose of 240 mg/kg/day, no drug was detected in fetal plasma 1 hour after dosing. Fetal plasma drug levels 2 hours after dosing were approximately 3% of maternal plasma drug levels. In dogs, at a maternal dose of 80 mg/kg/day, fetal plasma drug levels were approximately 50% of maternal plasma drug levels both 1 and 2 hours after dosing. In rats, at maternal doses of 40 and 640 mg/kg/day, fetal plasma drug levels were approximately 10 to 15% and 10 to 20% of maternal plasma drug levels 1 and 2 hours after dosing, respectively.

Indinavir was administered to Rhesus monkeys during the third trimester of pregnancy (at doses up to 160 mg/kg twice daily) and to neonatal Rhesus monkeys (at doses up to 160 mg/kg twice daily). When administered to neonates, indinavir caused an exacerbation of the transient physiologic hyperbilirubinemia seen in this species after birth; serum bilirubin values were approximately fourfold above controls at 160 mg/kg twice daily. A similar exacerbation did not occur in neonates after in utero exposure to indinavir during the third trimester of pregnancy. In Rhesus monkeys, fetal plasma drug levels were approximately 1 to 2% of maternal plasma drug levels approximately 1 hour after maternal dosing at 40, 80, or 160 mg/kg twice daily.

Hyperbilirubinemia has occurred during treatment with CRIXIVAN (see PRECAUTIONS and ADVERSE REACTIONS). It is unknown whether CRIXIVAN administered to the mother in the perinatal period will exacerbate physiologic hyperbilirubinemia in neonates.

There are no adequate and well-controlled studies in pregnant women. CRIXIVAN should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Antiviral Pregnancy Registry

To monitor maternal-fetal outcomes of pregnant women exposed to CRIXIVAN, an Antiretroviral Pregnancy Registry has been established. Physicians are encouraged to register patients by calling 1-800-258-4263.

Nursing Mothers

Studies in lactating rats have demonstrated that indinavir is excreted in milk. Although it is not known whether CRIXIVAN is excreted in human milk, there exists the potential for adverse effects from indinavir in nursing infants. Mothers should be instructed to discontinue nursing if they are receiving CRIXIVAN. This is consistent with the recommendation by the U.S. Public Health Service Centers for Disease Control and Prevention that HIV-infected mothers not breast-feed their infants to avoid risking postnatal transmission of HIV.
**Pediatric Use**

The optimal dosing regimen for use of indinavir in pediatric patients has not been established. A dose of 500 mg/m² every eight hours has been studied in uncontrolled studies of 70 children, 3 to 18 years of age. The pharmacokinetic profiles of indinavir at this dose were not comparable to profiles previously observed in adults receiving the recommended dose (see CLINICAL PHARMACOLOGY, Pediatric). Although viral suppression was observed in some of the 32 children who were followed on this regimen through 24 weeks, a substantially higher rate of nephrolithiasis was reported when compared to adult historical data (see WARNINGS, Nephrolithiasis/Urolithiasis). Physicians considering the use of indinavir in pediatric patients without other protease inhibitor options should be aware of the limited data available in this population and the increased risk of nephrolithiasis.

**Geriatric Use**

Clinical studies of CRIXIVAN did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal or cardiac function and of concomitant disease or other drug therapy.

**ADVERSE REACTIONS**

**Clinical Trials in Adults**

Nephrolithiasis/urolithiasis, including flank pain with or without hematuria (including microscopic hematuria), has been reported in approximately 12.4% (301/2429; range across individual trials: 4.7% to 34.4%) of patients receiving CRIXIVAN at the recommended dose in clinical trials with a median follow-up of 47 weeks (range: 1 day to 242 weeks; 2238 patient-years follow-up). The cumulative frequency of nephrolithiasis events increases with duration of exposure to CRIXIVAN; however, the risk over time remains relatively constant. Of the patients treated with CRIXIVAN who developed nephrolithiasis/urolithiasis in clinical trials during the double-blind phase, 2.8% (7/246) were reported to develop hydronephrosis and 4.5% (11/246) underwent stent placement. Following the acute episode, 4.9% (12/246) of patients discontinued therapy. (See WARNINGS and DOSAGE AND ADMINISTRATION, Nephrolithiasis/Urolithiasis.)

Asymptomatic hyperbilirubinemia (total bilirubin ≥2.5 mg/dL), reported predominantly as elevated indirect bilirubin, has occurred in approximately 14% of patients treated with CRIXIVAN. In <1% this was associated with elevations in ALT or AST.

Hyperbilirubinemia and nephrolithiasis/urolithiasis occurred more frequently at doses exceeding 2.4 g/day compared to doses ≤2.4 g/day.

Clinical adverse experiences reported in ≥2% of patients treated with CRIXIVAN alone, CRIXIVAN in combination with zidovudine or zidovudine plus lamivudine, zidovudine alone, or zidovudine plus lamivudine are presented in Table 5.
### Table 5
Clinical Adverse Experiences Reported in ≥2% of Patients

<table>
<thead>
<tr>
<th>Adverse Experience</th>
<th>Study 028</th>
<th>Study ACTG 320</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>CRIXIVAN</td>
<td>Zidovudine</td>
</tr>
<tr>
<td></td>
<td>Percent</td>
<td>Percent</td>
</tr>
<tr>
<td></td>
<td>(n=332)</td>
<td>(n=332)</td>
</tr>
<tr>
<td><strong>Body as a Whole</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>16.6</td>
<td>16.0</td>
</tr>
<tr>
<td>Asthenia/fatigue</td>
<td>2.1</td>
<td>4.2</td>
</tr>
<tr>
<td>Fever</td>
<td>1.5</td>
<td>1.5</td>
</tr>
<tr>
<td>Malaise</td>
<td>2.1</td>
<td>2.7</td>
</tr>
<tr>
<td><strong>Digestive System</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nausea</td>
<td>11.7</td>
<td>31.9</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>3.3</td>
<td>3.0</td>
</tr>
<tr>
<td>Vomiting</td>
<td>8.4</td>
<td>17.8</td>
</tr>
<tr>
<td>Acid regurgitation</td>
<td>2.7</td>
<td>5.4</td>
</tr>
<tr>
<td>Anorexia</td>
<td>2.7</td>
<td>5.4</td>
</tr>
<tr>
<td>Appetite increase</td>
<td>2.1</td>
<td>1.5</td>
</tr>
<tr>
<td>Dyspepsia</td>
<td>1.5</td>
<td>2.7</td>
</tr>
<tr>
<td>Jaundice</td>
<td>1.5</td>
<td>2.1</td>
</tr>
<tr>
<td><strong>Hemic and Lymphatic System</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anemia</td>
<td>0.6</td>
<td>1.2</td>
</tr>
<tr>
<td><strong>Musculoskeletal System</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Back pain</td>
<td>8.4</td>
<td>4.5</td>
</tr>
<tr>
<td><strong>Nervous System/Psychiatric</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Headache</td>
<td>5.4</td>
<td>9.6</td>
</tr>
<tr>
<td>Dizziness</td>
<td>3.0</td>
<td>3.9</td>
</tr>
<tr>
<td>Somnolence</td>
<td>2.4</td>
<td>3.3</td>
</tr>
<tr>
<td><strong>Skin and Skin Appendage</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pruritus</td>
<td>4.2</td>
<td>2.4</td>
</tr>
<tr>
<td>Rash</td>
<td>1.2</td>
<td>0.6</td>
</tr>
<tr>
<td><strong>Respiratory System</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cough</td>
<td>1.5</td>
<td>0.3</td>
</tr>
<tr>
<td>Difficulty breathing/ dyspnea/shortness</td>
<td>0</td>
<td>0.6</td>
</tr>
<tr>
<td>of breath</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Urogenital System</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nephrolithiasis/urolithiasis*</td>
<td>8.7</td>
<td>7.8</td>
</tr>
<tr>
<td>Dysuria</td>
<td>1.5</td>
<td>2.4</td>
</tr>
<tr>
<td><strong>Special Senses</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Taste perversion</td>
<td>2.7</td>
<td>8.4</td>
</tr>
</tbody>
</table>

* Including renal colic, and flank pain with and without hematuria

In Phase I and II controlled trials, the following adverse events were reported significantly more frequently by those randomized to the arms containing CRIXIVAN than by those randomized to nucleoside analogues: rash, upper respiratory infection, dry skin, pharyngitis, taste perversion.

Selected laboratory abnormalities of severe or life-threatening intensity reported in patients treated with CRIXIVAN alone, CRIXIVAN in combination with zidovudine or zidovudine plus lamivudine, zidovudine alone, or zidovudine plus lamivudine are presented in Table 6.
Table 6
Selected Laboratory Abnormalities of Severe or Life-threatening Intensity
Reported in Studies 028 and ACTG 320

<table>
<thead>
<tr>
<th></th>
<th>CRIXIVAN (n=329)</th>
<th>Study 028</th>
<th>Zidovudine (n=320)</th>
<th>Percent</th>
<th>Study ACTG 320</th>
<th>CRIXIVAN plus Lamivudine (n=571)</th>
<th>Zidovudine plus Lamivudine (n=575)</th>
<th>Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hematology</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Decreased hemoglobin</td>
<td>0.6</td>
<td>0.9</td>
<td>3.3</td>
<td>2.4</td>
<td>3.5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Decreased platelet</td>
<td>0.9</td>
<td>0.9</td>
<td>1.8</td>
<td>0.2</td>
<td>0.9</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>count &lt;50 THS/mm³</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Decreased neutrophils</td>
<td>2.4</td>
<td>2.2</td>
<td>6.7</td>
<td>5.1</td>
<td>14.6</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>count &lt;0.75 THS/mm³</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Blood chemistry</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Increased ALT &gt;500% ULN*</td>
<td>4.9</td>
<td>4.1</td>
<td>3.0</td>
<td>2.6</td>
<td>2.6</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Increased AST &gt;500% ULN</td>
<td>3.7</td>
<td>2.8</td>
<td>2.7</td>
<td>3.3</td>
<td>2.8</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total serum bilirubin</td>
<td>11.9</td>
<td>9.7</td>
<td>0.6</td>
<td>6.1</td>
<td>1.4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Increased serum amylase</td>
<td>2.1</td>
<td>1.9</td>
<td>1.8</td>
<td>0.9</td>
<td>0.3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;200% ULN</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Increased glucose &gt;250 mg/dL</td>
<td>0.9</td>
<td>0.9</td>
<td>0.6</td>
<td>1.6</td>
<td>1.9</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Increased creatinine</td>
<td>0</td>
<td>0</td>
<td>0.6</td>
<td>0.2</td>
<td>0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;300% ULN</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Upper limit of the normal range.

**Post-Marketing Experience**

**Body As A Whole:** redistribution/accumulation of body fat (see PRECAUTIONS, Fat Redistribution).

**Cardiovascular System:** cardiovascular disorders including myocardial infarction and angina pectoris; cerebrovascular disorder.

**Digestive System:** liver function abnormalities; hepatitis including reports of hepatic failure (see WARNINGS); pancreatitis; jaundice; abdominal distention; dyspepsia.

**Hematologic:** increased spontaneous bleeding in patients with hemophilia (see PRECAUTIONS); acute hemolytic anemia (see WARNINGS).

**Endocrine/Metabolic:** new onset diabetes mellitus, exacerbation of pre-existing diabetes mellitus, hyperglycemia (see WARNINGS).

**Hypersensitivity:** anaphylactoid reactions; urticaria; vasculitis.

**Musculoskeletal System:** arthralgia.

**Nervous System/Psychiatric:** oral paresthesia; depression.

**Skin and Skin Appendage:** rash including erythema multiforme and Stevens-Johnson Syndrome; hyperpigmentation; alopecia; ingrown toenails and/or paronychia; pruritus.

**Urogenital System:** nephrolithiasis/uroolithiasis; in some cases resulting in renal insufficiency or acute renal failure; pyelonephritis with or without bacteremia (see WARNINGS); interstitial nephritis sometimes with indinavir crystal deposits; in some patients, the interstitial nephritis did not resolve following discontinuation of CRIXIVAN; leukocyturia; (see PRECAUTIONS), crystalluria; dysuria.

**Laboratory Abnormalities**

Increased serum triglycerides; increased serum cholesterol.

**OVERDOSAGE**

There have been more than 60 reports of acute or chronic human overdosage (up to 23 times the recommended total daily dose of 2400 mg) with CRIXIVAN. The most commonly reported symptoms were renal (e.g., nephrolithiasis/uroolithiasis, flank pain, hematuria) and gastrointestinal (e.g., nausea, vomiting, diarrhea).

It is not known whether CRIXIVAN is dialyzable by peritoneal or hemodialysis.
DOSAGE AND ADMINISTRATION

The recommended dosage of CRIVXIVAN is 800 mg (usually two 400-mg capsules) orally every 8 hours.
CRIVXIVAN must be taken at intervals of 8 hours. For optimal absorption, CRIVXIVAN should be administered without food but with water 1 hour before or 2 hours after a meal. Alternatively, CRIVXIVAN may be administered with other liquids such as skim milk, juice, coffee, or tea, or with a light meal, e.g., dry toast with jelly, juice, and coffee with skim milk and sugar; or corn flakes, skim milk and sugar. (See CLINICAL PHARMACOLOGY, Effect of Food on Oral Absorption.)
To ensure adequate hydration, it is recommended that adults drink at least 1.5 liters (approximately 48 ounces) of liquids during the course of 24 hours.

Concomitant Therapy (See CLINICAL PHARMACOLOGY, Drug Interactions, and/or PRECAUTIONS, Drug Interactions.)

Delavirdine
Dose reduction of CRIVXIVAN to 600 mg every 8 hours should be considered when administering delavirdine 400 mg three times a day.

Didanosine
If indinavir and didanosine are administered concomitantly, they should be administered at least one hour apart on an empty stomach (consult the manufacturer's product circular for didanosine).

Efavirenz
Dose increase of CRIVXIVAN to 1000 mg every 8 hours is recommended when administering efavirenz concurrently (consult the manufacturer's product circular for efavirenz).

Itraconazole
Dose reduction of CRIVXIVAN to 600 mg every 8 hours is recommended when administering itraconazole 200 mg twice daily concurrently.

Ketoconazole
Dose reduction of CRIVXIVAN to 600 mg every 8 hours is recommended when administering ketoconazole concurrently.

Rifaxin
Dose reduction of rifabutin to half the standard dose (consult the manufacturer's product circular for rifabutin) and a dose increase of CRIVXIVAN to 1000 mg (three 333-mg capsules) every 8 hours are recommended when rifabutin and CRIVXIVAN are coadministered.

Hepatic Insufficiency
The dosage of CRIVXIVAN should be reduced to 600 mg every 8 hours in patients with mild-to-moderate hepatic insufficiency due to cirrhosis.

Nephrolithiasis/Urolithiasis
In addition to adequate hydration, medical management in patients who experience nephrolithiasis/urolithiasis may include temporary interruption (e.g., 1 to 3 days) or discontinuation of therapy.

HOW SUPPLIED
CRIVXIVAN Capsules are supplied as follows:
No. 3755 — 100 mg capsules: semi-translucent white capsules coded "CRIVXIVAN™ 100 mg" in green. Available as:
   NDC 0006-0570-62 unit-of-use bottles of 180 (with desiccant).
No. 3756 — 200 mg capsules: semi-translucent white capsules coded "CRIVXIVAN™ 200 mg" in blue. Available as:
   NDC 0006-0571-43 unit-of-use bottles of 360 (with desiccant).
No. 3802 — 333 mg capsules: semi-translucent white capsules coded "CRIVXIVAN™ 333 mg" in red and a radial red band on the body. Available as:
   NDC 0006-0574-65 unit-of-use bottles of 135 (with desiccant).
No. 3758 — 400 mg capsules: semi-translucent white capsules coded "CRIVXIVAN™ 400 mg" in green. Available as:
   NDC 0006-0573-42 unit-dose packages of 42
NDC 0006-0573-40 unit-of-use bottles of 120 (with desiccant)
NDC 0006-0573-62 unit-of-use bottles of 180 (with desiccant)
NDC 0006-0573-54 unit-of-use bottles of 90 (with desiccant)
NDC 0006-0573-18 unit-of-use bottles of 18 (with desiccant).

Storage

**Bottles:** Store in a tightly-closed container at room temperature, 15-30°C (59-86°F). Protect from moisture.

CRIXIVAN Capsules are sensitive to moisture. CRIXIVAN should be dispensed and stored in the original container. The desiccant should remain in the original bottle.

**Unit-Dose Packages:** Store at room temperature, 15-30°C (59-86°F). Protect from moisture.

MERCK & CO., INC., Whitehouse Station, NJ 08889, USA

Issued January 2003
Printed in USA